Person
Efthymiou, Stephanie
|
|
Biography and Research Interest
Dr Stephanie Efthymiou is a neurogenetics researcher at the University College London (UCL), specialising in the genetic basis of rare early-onset neurological and developmental disorders, particularly epileptic and complex neurodevelopmental conditions. Her work integrates genomic discovery with functional validation to improve diagnosis, refine genotype-phenotype correlations, and advance disease modelling.
Dr Efthymiou adopts a gene-agnostic approach, applying whole exome and genome sequencing to identify novel disease-associated genes in unsolved patient cohorts. She has particular expertise in variant interpretation, deep phenotyping, and collaborative clinical genomics, working closely with clinicians to translate genetic findings into meaningful insights for patient care. She has contributed to large-scale rare disease initiatives, including Solve-RD, and currently serves as a work package leader and UCL institutional lead within the ERDERA consortium. She has also been actively involved in the SYNAPS Patient Group, contributing to collaborative efforts aimed at building a biobank of samples and patient cells, advancing precision medicine approaches for rare neurological disorders through international data sharing and coordinated research strategies.
A central pillar of her research is meaningful patient inclusion and engagement. She works closely with affected individuals, families, clinicians, and patient support groups to ensure that research priorities align with lived experience and clinically relevant needs. Dr Efthymiou is particularly committed to improving representation of underrepresented and geographically diverse populations in genomic research, recognising the importance of equitable access to advanced diagnostics and the need to reduce bias in genomic datasets. By expanding recruitment beyond traditionally studied populations, her work contributes to more accurate variant interpretation, fairer diagnostic pathways, and broader global impact.
Her research extends beyond gene discovery to functional characterisation using patient-derived cellular models, including fibroblasts and induced pluripotent stem cells (iPSCs). She applies neuronal differentiation systems and molecular assays to investigate disease mechanisms, with a focus on disorders affecting motor and cortical neuronal development. Dr Efthymiou also has expertise in advanced genomic technologies, including long-read sequencing and optical genome mapping, particularly for complex or previously unresolved neuromuscular and neurodevelopmental conditions.
Through integrating genomics, functional biology, patient partnership, equitable population representation, and international collaboration, her work aims to accelerate diagnosis, improve mechanistic understanding, and contribute to precision medicine approaches for rare neurological disease.
Dr Efthymiou adopts a gene-agnostic approach, applying whole exome and genome sequencing to identify novel disease-associated genes in unsolved patient cohorts. She has particular expertise in variant interpretation, deep phenotyping, and collaborative clinical genomics, working closely with clinicians to translate genetic findings into meaningful insights for patient care. She has contributed to large-scale rare disease initiatives, including Solve-RD, and currently serves as a work package leader and UCL institutional lead within the ERDERA consortium. She has also been actively involved in the SYNAPS Patient Group, contributing to collaborative efforts aimed at building a biobank of samples and patient cells, advancing precision medicine approaches for rare neurological disorders through international data sharing and coordinated research strategies.
A central pillar of her research is meaningful patient inclusion and engagement. She works closely with affected individuals, families, clinicians, and patient support groups to ensure that research priorities align with lived experience and clinically relevant needs. Dr Efthymiou is particularly committed to improving representation of underrepresented and geographically diverse populations in genomic research, recognising the importance of equitable access to advanced diagnostics and the need to reduce bias in genomic datasets. By expanding recruitment beyond traditionally studied populations, her work contributes to more accurate variant interpretation, fairer diagnostic pathways, and broader global impact.
Her research extends beyond gene discovery to functional characterisation using patient-derived cellular models, including fibroblasts and induced pluripotent stem cells (iPSCs). She applies neuronal differentiation systems and molecular assays to investigate disease mechanisms, with a focus on disorders affecting motor and cortical neuronal development. Dr Efthymiou also has expertise in advanced genomic technologies, including long-read sequencing and optical genome mapping, particularly for complex or previously unresolved neuromuscular and neurodevelopmental conditions.
Through integrating genomics, functional biology, patient partnership, equitable population representation, and international collaboration, her work aims to accelerate diagnosis, improve mechanistic understanding, and contribute to precision medicine approaches for rare neurological disease.
Non-Zebrafish Publications